PAR reports successful phase 2 clinical trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
In the deck
Earlier from Paradigm Biopharmaceuticals
- Paradigm reports consistent oa pain reduction
- Paradigms AGM Presentation
- Paradigm in-licenses treatment for rare joint disease
- Paradigm receives $2.32m R&D tax incentive refund
- PAR reports pain reduction in 145 people with osteoarthritis
Later from Paradigm Biopharmaceuticals
- Presentation of phase 2 clinical trial results
- Paradigms supplementary phase 2B data
- Paradigms orphan phase 2/3 clinical program progresses
- S&P DJI Announces March 2019 Quarterly Rebalance
- Paradigm (PAR) Updated Investor Presentation
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals